Cancer and Hematologic Disorders – CHD
The Cancer and Hematologic Disorders (CHD) study section reviews applications that seek to understand the etiology, determinants, distribution and outcomes of cancer and hematologic disorders, conditions and phenotypes from a population health perspective. Applications reviewed will examine a range of exposures and risk factors for cancer and hematological disorders including but not limited to genetic, epigenetic, biological, biomedical and environmental risk factors. Studies reviewed in CHD have a population health focus, including consideration of health equity within and across populations. Applications that focus on the pathophysiology or the underlying mechanisms of these diseases and disorders especially those that primarily use animal or other experimental models are reviewed in other study sections.
Review Dates
Topics
- Studies addressing the incidence, prevalence, progression and consequences of hematologic disease and phenotypes in large populations, including but not limited to anemias, disorders of coagulation, lymphomas and leukemias
- Studies addressing the incidence, prevalence, progression and consequences of cancers in large populations including the focus on early detection, survivorship and recurrence
- Studies examining the effects of environmental and other exposures on incidence, progression, and outcomes related to cancer and hematologic disorders in large populations, especially with a focus on the disease or disorder outcome rather than the exposure
- Studies of incidence, prevalence and determinants of co-morbidities and multi-morbidities in populations with cancer and hematological disorders
- Applications may use methodologies and study designs including cohort, case-control, prospective, longitudinal, retrospective, clinical trial, cross-sectional, surveillance, genetics, epigenetics, omics (i.e. genomics, transcriptomics, proteomics, metabolomics, epigenomics, metagenomics) and assessment of gene-environment interactions
Shared Interests and Overlaps
There are shared interests in risk and protective factors to mark cancer incidence, progression and treatment outcomes with Molecular Cancer Diagnosis and Classification (MCDC). Applications that apply validated biomarkers to cancer studies in human subpopulations are reviewed in CHD. Applications that emphasize discovery and validation of biomarkers for cancer (pre-epidemiology studies) are reviewed in MCDC.
There are shared interests in genetic predisposition to cancer with Cancer Genetics Study Section (CG). Applications that emphasize genetic epidemiology of cancer in human subpopulations relating genetic and epigenetic risk factors and biomarkers with cancer incidence and disease progression are reviewed in CHD. Applications that emphasize cancer genetic and epigenetic studies in both animals and humans with the aim of identifying genes and gene regulation that modifies susceptibility to cancer and molecular pathways involved in cancer pathogenesis are reviewed in CG.
There are shared interests in ethnic and racial disparities in cancer outcomes with Basic Mechanisms in Cancer Health Disparities (BMCD). Applications using a human population-based or epidemiological approach to characterizing behavioral, social, environmental, or genetic/epigenetic factors contributing to racial/ethnic disparities in cancer outcomes may be reviewed in CHD. Applications focused on identifying basic biological mechanisms underlying racial/ethnic disparities in cancer outcomes in both animal models and human studies will be reviewed in BMCD.
There are shared interests in social or environmental epidemiology applications that assess cancer outcomes with Social and Environmental Determinants of Health (SEDH). Applications that focus on cancer health outcomes incorporating environmental and/or social exposures as risk factors at the population level may be reviewed in CHD. Applications that focus on the environmental and/or social determinants or exposures that contribute to cancer outcomes at the population level are reviewed in SEDH.
There are shared interests in characterizing the role of lifestyle and health behaviors in cancer health outcomes at the population level with Lifestyle and Health Behaviors (LHB). Applications that focus on lifestyle and health behaviors as part of a panel of risk factors of cancer population health outcomes from a more biological and biomedical perspective are reviewed in CHD. Applications that focus on the lifestyle and health behaviors associated with cancer outcomes at the population level from a more behavioral perspective are reviewed in LHB.
There are shared interests in hematologic disorders with Clinical Integrative Cardiovascular and Hematological Sciences (CCHS). Applications that emphasize epidemiologic studies of hematologic disorders and clinical trials aimed at answering population-based questions about hematologic disease development, progression and treatment outcomes are reviewed in CHD. Clinical studies of the pathology associated with hematological dysfunction typically with small sample sizes are reviewed in CCHS.
There are shared interests in assessing genetic predisposition to diseases in large population samples with Genetics of Health and Disease (GHD). Applications that emphasize how these factors contribute to health outcomes in human subpopulations are reviewed in CHD. Applications that emphasize discovery of genetic, genomic, epigenomic elements and molecular signatures are reviewed in GHD.
